Zoetis’ (ZTS) Overweight Rating Reiterated at Piper Jaffray Cos.

Piper Jaffray Cos. reaffirmed their overweight rating on shares of Zoetis Inc. (NYSE:ZTS) in a research note released on Thursday morning. Piper Jaffray Cos. currently has a $61.00 price objective on the stock.

A number of other equities analysts also recently commented on the stock. JPMorgan Chase & Co. reiterated a hold rating and issued a $53.00 target price on shares of Zoetis in a report on Thursday, November 3rd. Zacks Investment Research downgraded shares of Zoetis from a buy rating to a hold rating in a report on Tuesday, November 15th. Bank of America Corp. assumed coverage on shares of Zoetis in a report on Thursday, September 29th. They set a buy rating and a $60.00 price objective on the stock. Argus upped their price objective on shares of Zoetis from $54.00 to $58.00 and gave the company a below average rating in a report on Friday, September 9th. Finally, Credit Suisse Group AG restated an outperform rating and set a $60.00 price objective on shares of Zoetis in a report on Tuesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of Buy and an average price target of $56.77.

Zoetis (NYSE:ZTS) opened at 52.39 on Thursday. The firm has a 50-day moving average of $50.21 and a 200 day moving average of $50.07. Zoetis has a 52-week low of $38.26 and a 52-week high of $53.14. The company has a market capitalization of $25.87 billion, a P/E ratio of 37.77 and a beta of 1.06.

Zoetis (NYSE:ZTS) last announced its earnings results on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, topping the Zacks’ consensus estimate of $0.46 by $0.06. The business earned $1.20 billion during the quarter, compared to the consensus estimate of $1.22 billion. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The firm’s revenue was up 2.2% on a year-over-year basis. During the same period in the previous year, the company posted $0.50 earnings per share. Equities analysts predict that Zoetis will post $1.94 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this report can be accessed at https://sportsperspectives.com/2016/12/20/zoetis-zts-overweight-rating-reiterated-at-piper-jaffray-cos.html.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 1st. Shareholders of record on Friday, January 20th will be given a $0.105 dividend. This represents a $0.42 annualized dividend and a yield of 0.80%. The ex-dividend date of this dividend is Wednesday, January 18th. This is a positive change from Zoetis’s previous quarterly dividend of $0.10. Zoetis’s dividend payout ratio is currently 27.54%.

In other Zoetis news, insider Roxanne Lagano sold 9,797 shares of the company’s stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $50.43, for a total value of $494,062.71. Following the sale, the insider now owns 8,063 shares in the company, valued at approximately $406,617.09. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Kristin C. Peck sold 10,092 shares of the company’s stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $49.55, for a total value of $500,058.60. Following the completion of the sale, the insider now owns 22,768 shares in the company, valued at approximately $1,128,154.40. The disclosure for this sale can be found here. 0.05% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue acquired a new position in shares of Zoetis during the second quarter worth about $5,328,000. Nordea Investment Management AB raised its position in shares of Zoetis by 0.7% in the second quarter. Nordea Investment Management AB now owns 24,432 shares of the company’s stock worth $1,160,000 after buying an additional 163 shares during the period. BLB&B Advisors LLC raised its position in shares of Zoetis by 1.7% in the second quarter. BLB&B Advisors LLC now owns 54,625 shares of the company’s stock worth $2,593,000 after buying an additional 923 shares during the period. Eagle Asset Management Inc. raised its position in shares of Zoetis by 1.1% in the second quarter. Eagle Asset Management Inc. now owns 78,205 shares of the company’s stock worth $3,711,000 after buying an additional 847 shares during the period. Finally, Barrett Asset Management LLC acquired a new position in shares of Zoetis during the second quarter worth about $237,000. Institutional investors and hedge funds own 92.31% of the company’s stock.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

5 Day Chart for NYSE:ZTS

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply